OAM
EW icon

Ostrum Asset Management’s Edwards Lifesciences EW Stock Holding History

Ostrum Asset Management’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.32M Sell
53,920
-132
-0.2% -$10.9K 0.24% 58
2025
Q4 		$4.61M Buy
54,052
+461
+0.9% +$37.8K 0.22% 60
2025
Q3 		$4.17M Buy
53,591
+47,491
+779% +$3.71M 0.19% 88
2025
Q2 		$477K Buy
6,100
+4,286
+236% +$320K 0.02% 414
2025
Q1 		$131K Sell
1,814
-48
-3% -$3.44K 0.01% 540
2024
Q4 		$138K Sell
1,862
-11,273
-86% -$789K 0.01% 549
2024
Q3 		$867K Buy
13,135
+160
+1% +$11.6K 0.07% 337
2024
Q2 		$1.2M Sell
12,975
-6,865
-35% -$608K 0.1% 280
2024
Q1 		$1.9M Hold
19,840
– – 0.15% 233
2023
Q4 		$1.51M Buy
19,840
+9,248
+87% +$643K 0.13% 242
2023
Q3 		$734K Sell
10,592
-5,631
-35% -$453K 0.07% 374
2023
Q2 		$1.53M Buy
16,223
+41
+0.3% +$3.56K 0.13% 227
2023
Q1 		$1.34M Buy
+16,182
New +$1.27M 0.12% 245

Other funds holding EW

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Ostrum Asset Management's EW Position: Q1 2026 in Review

Ostrum Asset Management reduced its Edwards Lifesciences (EW) stake by 0.24% in Q1 2026, selling an estimated $10.9K and leaving 53,920 shares worth $4.32M. The position accounts for 0.24% of the portfolio, ranked #58.

Ostrum Asset Management first reported a position in EW in Q1 2023 and has held it in 13 quarters since. The position peaked at $4.61M in Q4 2025. 1,283 funds tracked by Wall St. Rank hold EW as of Q1 2026.

  • Ostrum Asset Management held 53,920 shares of Edwards Lifesciences worth $4.32M as of Q1 2026.
  • Ostrum Asset Management sold 132 Edwards Lifesciences shares in Q1 2026, an estimated $10.9K.
  • Edwards Lifesciences made up 0.24% of Ostrum Asset Management's portfolio in Q1 2026, its #58 holding.
  • Ostrum Asset Management first reported a position in Edwards Lifesciences in Q1 2023 and has held it in 13 quarters since.
  • Ostrum Asset Management's Edwards Lifesciences position peaked at $4.61M in Q4 2025.
  • 1,283 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2026.

Based on Ostrum Asset Management's 13F filing for Q1 2026, filed 14 May 2026.